Nivolumab plus Ipilimumab in Advanced Melanoma

D. Wolchok, Jedd; M. Kluger, Harriet; K. Callahan, Margaret; A. Postow, Michael; A. Rizvi, Naiyer; M. Lesokhin, Alexander; H. Segal, Neil; E. Ariyan, Charlotte; Gordon, RuthAnn; Reed, Kathleen; M. Burke, Matthew; Caldwell, Anne; Anne Kronenberg, Stephanie; Agunwamba, Blessing; Zhang, Xiaoling; Lowy, Israel; David Inzunza, H.; F. Feely, William; E. Horak, Christine; Hong, Quan; J. Korman, Alan; M. Wigginton, Jon; Gupta, Ashok; Sznol, Mario

doi:10.1056/nejmoa1302369

Public

Nivolumab plus Ipilimumab in Advanced Melanoma

Published in New England Journal of Medicine • Jun 2, 2013

Authors:

Jedd D. Wolchok

Harriet M. Kluger

Margaret K. Callahan

Abstract

BACKGROUND: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis of the...

Subject

Ipilimumab

Medicine

Nivolumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!